THE European Commission has
issued its first ever “paediatric use
marketing authorisation,” with
Buccolam (midazolam for buccal
administration) specifically licensed
to treat convulsions and epileptic
seizures in children aged three
months to 18 years.
The move has been welcomed by
the UK Medicines and Healthcare
products Regulatory Agency, which
has long advocated for specific
children’s-only medicines - rather
than simply reduced doses of adult
medications.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Sep 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Sep 11
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.